Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAT2A | P31153 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24110949 | 0.89 | HTR7 (0.44) | SMN1; SMN2PNP | |
| SCHEMBL24089976 | 0.88 | TP53 (0.52) | TP53SMN1; SMN2MAPT | |
| SCHEMBL24110926 | 0.84 | TUBB4A (0.44) | SMN1; SMN2 | |
| SCHEMBL24111015 | 0.84 | MEN1 (0.47) | TP53SMN1; SMN2MAPTMAT2A | |
| SCHEMBL24089978 | 0.83 | TUBB4A (0.48) | SMN1; SMN2 | |
| SCHEMBL23958278 | 0.82 | TUBB4A (0.45) | MAT2ACYP19A1 | |
| SCHEMBL30025728 | 0.82 | TUBB4A (0.45) | MAT2ACYP19A1 | |
| SCHEMBL24110934 | 0.82 | NPC1 (0.40) | — | |
| SCHEMBL29738613 | 0.82 | NPC1 (0.40) | — | |
| SCHEMBL24090094 | 0.81 | TP53 (0.48) | TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | PDE10A 2576/4885TP53 3842/4885SMN1; SMN2 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.